Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second-leading cause of cancer-related deaths in Europe by 2040. Unlike other…
Teresa Macarulla
Recently presented at the 2024 ASCO Annual Meeting and published in parallel in The Lancet Oncology, results of the OPTIMIZE-1…
Published in the journal ESMO Gastrointestinal Oncology, results of a VHIO-led retrospective and multicenter study show that 3.4% of pancreatic…
Biliary tract cancer (BTC) poses a distinctive challenge in oncology, mainly due to diagnosis at late-stage and limited effective systemic…
Peptomyc has received full study approval for its Phase Ib clinical trial evaluating the combination of its first-in-class MYC inhibitor…
Pancreatic cancer accounts for almost as many deaths (466,000) as cases (496,000) because of its poor prognosis. It is the…
Futibatinib, an advanced FGFR inhibitor, has demonstrated effectiveness in impeding tumor growth among patients with FGFR-altered tumors. What is Intrahepatic…
Metastatic Pancreatic Ductal Andenocarcinoma (mPDAC) is an aggressive type of cancer that is most frequently detected at advanced stages with…
Recently published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), VHIO investigators have established…
Published in the flagship journal of the European Society for Medical Oncology, Annals of Oncology, renowned leaders in the field…
